NCT02830308

Brief Summary

Background: There are many endocrine and metabolic-related conditions. Two well-known disorders include diabetes and thyroid disease. Some of these diseases are caused by a change in genes. Researchers want to identify the genes involved in these disorders. They hope this will help them learn more about these diseases. Objectives: To learn more about conditions that affect the hormone-secreting glands (endocrine glands) in adults. To train doctors to diagnose and treat people with endocrine or metabolic conditions. Eligibility: Adults age 18 years and older with a known or suspected endocrine disorder. Relatives ages 18 years and older. Doctors will review all requests and available medical records to determine final eligibility for the protocol. Design: Participants will have a medical history and physical exam. Most participants will have 1 visit, and may have follow up visits if necessary. They may have tests, surgery, or other procedures to help diagnose or treat their condition. These could include:

  • Blood, urine, and saliva tests
  • Imaging tests. These may include X-ray, ultrasound, or scans.
  • Sleep study
  • Medical photographs
  • Visits with other specialists at NIH Participants will provide blood, urine, saliva, or tissue samples. Some of these samples may be stored in the freezer for future studies. Participants may be asked to participate in genetic testing. They will give a blood or saliva sample for this.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,250

participants targeted

Target at P75+ for all trials

Timeline
44mo left

Started Jul 2016

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress73%
Jul 2016Dec 2029

First Submitted

Initial submission to the registry

July 9, 2016

Completed
Same day until next milestone

Study Start

First participant enrolled

July 9, 2016

Completed
3 days until next milestone

First Posted

Study publicly available on registry

July 12, 2016

Completed
13.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 20, 2029

Expected
11 days until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2029

Last Updated

April 27, 2026

Status Verified

April 23, 2026

Enrollment Period

13.5 years

First QC Date

July 9, 2016

Last Update Submit

April 24, 2026

Conditions

Keywords

HormonesEndocrineHypercortisolismBoneHypothalamic-Pituitary DysfunctionNatural History

Outcome Measures

Primary Outcomes (1)

  • Recruit a diverse population of adult subjects with a known or suspected endocrine or metabolic disorder in order to provide NIDDK investigators and trainees with hands-on experience related to the diagnosis, management, treatment, and follow-up...

    The overall purpose of endocrine evaluations under this protocol is to support our clinical training and research missions.

    12/31/2036

Study Arms (1)

Adults with known or suspected endocrine or metabolic dissorde

Adults with known or suspected endocrine or metabolic dissorders

Eligibility Criteria

Age18 Years - 100 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Primary Clinical

You may qualify if:

  • Participants with known or suspected endocrine disorder age 18 years and older are eligible for this protocol. Protocol investigators will make the actual selection of subjects most appropriate for clinical evaluation.
  • Relatives ages 18 years and older may be enrolled if clinically indicated for the diagnosis of a proband.

You may not qualify if:

  • Anyone under the age of 18 years old
  • Any medical, physical, psychiatric, or social conditions, which, in the opinion of the investigators, would make participation in this protocol not in the best interest of the subject. Subjects who are critically ill, unstable, or with severe organ failure that may affect/limit the endocrine evaluation and place unsustainable demands on Clinical Center or NIDDK resources.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States

RECRUITING

Related Publications (1)

  • Abd-Elmoniem KZ, Edwan JH, Dietsche KB, Villalobos-Perez A, Shams N, Matta J, Baumgarten L, Qaddumi WN, Dixon SA, Chowdhury A, Stagliano M, Mabundo L, Wentzel A, Hadigan C, Gharib AM, Chung ST. Endothelial Dysfunction in Youth-Onset Type 2 Diabetes: A Clinical Translational Study. Circ Res. 2024 Aug 30;135(6):639-650. doi: 10.1161/CIRCRESAHA.124.324272. Epub 2024 Jul 29.

Related Links

MeSH Terms

Conditions

Endocrine System DiseasesCushing Syndrome

Condition Hierarchy (Ancestors)

Adrenocortical HyperfunctionAdrenal Gland Diseases

Study Officials

  • Marissa F Lightbourne, M.D.

    National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Marissa F Lightbourne, M.D.

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
OTHER
Sponsor Type
NIH
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 9, 2016

First Posted

July 12, 2016

Study Start

July 9, 2016

Primary Completion (Estimated)

December 20, 2029

Study Completion (Estimated)

December 31, 2029

Last Updated

April 27, 2026

Record last verified: 2026-04-23

Data Sharing

IPD Sharing
Will share

De-identified results from clinical trials will be posted on cctrials.gov

Shared Documents
STUDY PROTOCOL
Time Frame
Not otherwise specified in protocol.
Access Criteria
Only investigators will have access to the data. Publications will not include subject names, nor will they contain personal identifying information. De-identified results from clinical trials will be posted on cctrials.gov

Locations